Specifically in NSCLC, mutations in genes including KEAP1, SMARCA4, and CDKN2A have been associated with resistance to KRASG12C inhibitors (9, 10, 57), and the mutation in STK11 has been associated with sensitivity to KRASG12C inhibition (9, 10). This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.